Flag of the European Union EU Clinical Trials Register Help

Clinical trials for acne

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    181 result(s) found for: acne. Displaying page 7 of 10.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    EudraCT Number: 2009-016240-40 Sponsor Protocol Number: BENER53VER Start Date*: 2010-06-15
    Sponsor Name:VERISFIELD (UK) LTD, GREEK BRANCH
    Full Title: MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE WITH THE REFERENCE PRODUCT CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE THERAPY WITH THE COMBINATION OF BENZOYL PEROXIDE-ERYTHROMYCIN...
    Medical condition: ACNE VULGARIS
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2014-003610-86 Sponsor Protocol Number: EMCD1403 Start Date*: 2014-11-14
    Sponsor Name:
    Full Title: A double blind randomized controlled trial comparing the efficacy of 7% lidocaine / 7% tetracaine cream versus 2,5% lidocaine / 2,5% prilocaine cream for local anaesthesia during laser treatment of...
    Medical condition: Pain during laser treatment of: 1. Tattoo 2. Acne keloidalis nuchae
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003406-24 Sponsor Protocol Number: M11-810 Start Date*: 2012-03-14
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa
    Medical condition: Hidradenitis Supperativa
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GR (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002988-33 Sponsor Protocol Number: IFX-1-P2.3 Start Date*: 2016-11-04
    Sponsor Name:InflaRx GmbH
    Full Title: An open label Phase II trial to evaluate the safety of IFX-1 in patients with moderate to severe Hidradenitis suppurativa
    Medical condition: Hidradenitis suppurativa
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2004-002367-24 Sponsor Protocol Number: PC TA001/04 Start Date*: 2004-10-20
    Sponsor Name:PhotoCure ASA
    Full Title: A blinded, prospective, randomised, placebo-controlled, multi-centre, split-face study of photodynamic therapy with Metvix 160 mg/g cream in subjects with acne vulgaris.
    Medical condition: Moderate inflammatory acne vulgaris.
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004753-68 Sponsor Protocol Number: HidraQureS/2020 Start Date*: 2022-09-15
    Sponsor Name:Red Andaluza de Diseño y Traslación de Terapias Avanzadas-Fundación Progreso y Salud
    Full Title: Phase II, Single-Center, Randomized, Double-blind, Placebo-controlled Clinical Trial to determine the safety and efficacy of the use of allogeneic adipose tissue adult stem mesenchymal cells in the...
    Medical condition: Hidradenitis suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001440-99 Sponsor Protocol Number: ANB019-208 Start Date*: 2021-08-25
    Sponsor Name:AnaptysBio Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects with Hidradenitis Suppurativa
    Medical condition: Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001981-13 Sponsor Protocol Number: INCB54707204 Start Date*: 2021-03-02
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
    Medical condition: Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2022-003562-20 Sponsor Protocol Number: 2018-018 Start Date*: 2023-03-07
    Sponsor Name:INSTITUT PASTEUR
    Full Title: A Multicentric Randomized Double-Blind Phase 3 Trial Evaluating the Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Active Hidradenitis Suppurativa Patients versus Tetracycline Derivative
    Medical condition: Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005754-28 Sponsor Protocol Number: PAPA-Can Start Date*: 2023-07-10
    Sponsor Name:IRCCS ISTITUTO GIANNINA GASLINI
    Full Title: A double-blind, placebo-controlled, randomized withdrawal study of canakinumab in pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome
    Medical condition: PAPA syndrome (Pyogenic Arthritis, Pyoderma gangrenosum and Acne)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10072225 PAPA syndrome LLT
    20.0 100000004850 10072225 PAPA syndrome LLT
    20.0 100000004850 10072225 PAPA syndrome LLT
    20.0 100000004850 10072225 PAPA syndrome LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-002509-39 Sponsor Protocol Number: RD.03.SPR.102710 Start Date*: 2014-10-30
    Sponsor Name:GALDERMA R&D
    Full Title: Effect of Patient Education on Treatment Adherence and Satisfaction among Acne Patients Receiving Once-Daily EpiduoTM Gel Treatment in Primary Care Clinics
    Medical condition: Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    17.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004909-16 Sponsor Protocol Number: STF114543 Start Date*: 2016-08-03
    Sponsor Name:GlaxoSmithKline R&D Ltd
    Full Title: A Multicentre, Randomized, Assessor-blind, Comparator-Controlled, Parallel-Group Clinical Trial to Establish the Efficacy and Safety of Duac™(1% clindamycin as clindamycin phosphate and 5% benzoyl ...
    Medical condition: acne vulgaris
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-001448-13 Sponsor Protocol Number: RD.03.SPR.105041 Start Date*: 2015-07-09
    Sponsor Name:Galderma R&D
    Full Title: Benzaknen® 5% Gel in combination with Dermotivin® Soft Liquid cleanser and non-comedogenic Cetaphil® Dermacontrol Moisturizer SPF30 in the treatment of mild-to-moderate acne vulgaris
    Medical condition: Acne vulgaris (AV)
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000122-21 Sponsor Protocol Number: M16-833 Start Date*: 2019-08-23
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa
    Medical condition: Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004765-90 Sponsor Protocol Number: DFD03-CD-004 Start Date*: 2016-07-13
    Sponsor Name:Dr. Reddy’s Laboratories, Ltd
    Full Title: A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks
    Medical condition: Acne vulgaris
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000232-12 Sponsor Protocol Number: SYNC-01-AC-P1 Start Date*: 2007-01-31
    Sponsor Name:Syntopix Group plc
    Full Title: Novel topical therapies for acne vulgaris: a randomised, controlled, double blind comparison of the antibacterial efficacy of 1% w/v formulations of tert-butylhydroquinone, zinc pyrithione and benz...
    Medical condition: Healthy volunteer study. The product under development will be used for the treatment of acne vulgaris.
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000859-27 Sponsor Protocol Number: HS_Apremilast Start Date*: 2017-01-23
    Sponsor Name:Erasmus University Medical Center
    Full Title: Efficacy and mode of action of apremilast (Otezla) in moderate hidradenitis suppurativa. An exploratory pilot study.
    Medical condition: Hidradenitis suppurativa, acne inversa, ectopic acne
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004606-24 Sponsor Protocol Number: 04.168-11 Start Date*: 2005-01-24
    Sponsor Name:Fujisawa GmbH
    Full Title: A randomized, open-label, monocentric clinical phase I/IV study in healthy human volunteers to evaluate the skin tolerability and cosmetic acceptance of three marketed anti-acne drugs (Differin® Cr...
    Medical condition:
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002551-42 Sponsor Protocol Number: HS0004 Start Date*: 2020-07-10
    Sponsor Name:UCB Biopharma SRL
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
    Medical condition: Hidradenitis Suppurativa (HS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) HU (Completed) CZ (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-001988-12 Sponsor Protocol Number: 1.2000 Start Date*: 2015-02-02
    Sponsor Name:Academic Medical Center, Amsterdam
    Full Title: Fractional CO2 laser assisted delivery of topical articaine and epinephrine solution vs. topical EMLA administration: a randomized controlled pilot study
    Medical condition: local anesthesia of the skin prior to laser therapy of acne and traumatic scars
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 04:55:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA